Market cap
$1 Mln
Revenue (TTM)
$133 Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 0.00 | 70.66 | 12.74 | -4.63 | -20.09 |
| EBIT | -- | 111.78 | 70.47 | 22.71 | -163.60 |
| Net Profit | 0.00 | -1,194.35 | -679.47 | -216.60 | -338.57 |
| EPS | -28.80 | -1,533.23 | -489.77 | -13.86 | -293.51 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| -38.37 | -32.87 | -7.72 | -19.78 | -35.45 |
| Net Margin
| -- | -78.05 | -340.28 | -- | -- |
| Return on equity
| 226.26 | 116.66 | -- | 786.07 | -53.86 |
| Return on Capital
| -71.76 | -54.02 | -- | -168.86 | -21.66 |
| Return on Assets
| -44.37 | -34.60 | -150.72 | -98.51 | -15.49 |
| Debt to Equity (x)
| -- | -- | 0.00 | -1.21 | 1.85 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
--
|
-168.86
|
-21.66
|
-24.75
|
-18.82
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
--
|
786.07
|
-53.86
|
-53.43
|
-36.30
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-150.72
Lower than Peers by 119.47
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
-150.72
|
-98.51
|
-15.49
|
-19.11
|
-13.91
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
-7.72
Higher than Peers by 74.88
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
-7.72
|
-19.78
|
-35.45
|
-59.89
|
-56.81
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
-340.28
Lower than Peers by 248.98
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
-340.28
|
-214.95
|
-55.59
|
-80.54
|
-47.64
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
12.74
Lower than Peers by 41.30
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
12.74
|
-0.01
|
-0.08
|
-0.16
|
-0.20
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
70.47
Higher than Peers by 71.48
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
70.47
|
44.66
|
45.62
|
11.05
|
-697.31
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
-679.47
Lower than Peers by 671.94
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
-679.47
|
-283.60
|
36.59
|
-4.38
|
63.51
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
-489.77
Lower than Peers by 504.00
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
-489.77
|
-5.75
|
0.83
|
0.26
|
0.66
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
-358.98
Lower than Peers by 348.85
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
-358.98
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
--
|
-1.21
|
1.85
|
1.26
|
1.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-1.19
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
-1.19
|
-1.19
|
0.02
|
0.05
|
0.32
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.33
Lower than Peers by 5.48
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
0.33
|
0.33
|
2.16
|
1.89
|
1.61
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
0.26
Lower than Peers by 5.44
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
0.26
|
0.26
|
1.83
|
1.55
|
1.40
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-14.70
Lower than Peers by 12.62
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
-14.70
|
-0.74
|
-1.49
|
-2.57
|
-2.84
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
12.97
Lower than Peers by 6.04
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
12.97
|
14.71
|
11.69
|
13.17
|
13.20
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
0.44
Higher than Peers by 0.38
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
0.44
|
0.46
|
0.28
|
0.24
|
0.21
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
--
|
48.38
|
47.55
|
52.63
|
50.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
--
|
114.65
|
188.45
|
211.45
|
293.71
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
--
|
93.04
|
131.87
|
278.22
|
630.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
--
|
69.99
|
104.13
|
-14.14
|
-286.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
--
|
-0.07
|
-0.03
|
-0.01
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.05
Lower than Peers by 5.27
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
0.05
|
-0.12
|
0.02
|
0.01
|
0.00
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.69
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
-0.69
|
21.34
|
-13.66
|
-3.28
|
-2.91
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
1
Lower than Peers by 141
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Acorda Therapeutics (ACOR)
|
1
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|